Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Multicenter Randomized Phase II Trial in NSCLC Stage IV and IIIB (T4 With Pleural Effusion) in Elderly Independent Patients the Schedule Docetaxel / Gemcitabine First Line Following by Erlotinib When Progression Versus Erlotinib First Line Following by/ Gemcitabine When Progression.
Authors not listed
Groupe Francais De Pneumo-Cancerologie · 2006
Abstract
The purpose of this study is to determine duration before progression of first-line treatment chemotherapy following erlotinib in second-line comparing erlotinib in first-line following chemotherapy in second-line in old patients with none small cell lung cancer.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Anonymous. (2006). A Multicenter Randomized Phase II Trial in NSCLC Stage IV and IIIB (T4 With Pleural Effusion) in Elderly Independent Patients the Schedule Docetaxel / Gemcitabine First Line Following by Erlotinib When Progression Versus Erlotinib First Line Following by/ Gemcitabine When Progression. <em>Groupe Francais De Pneumo-Cancerologie</em>. https://clinicaltrials.gov/study/NCT00418704
Vancouver
Anonymous. A Multicenter Randomized Phase II Trial in NSCLC Stage IV and IIIB (T4 With Pleural Effusion) in Elderly Independent Patients the Schedule Docetaxel / Gemcitabine First Line Following by Erlotinib When Progression Versus Erlotinib First Line Following by/ Gemcitabine When Progression. Groupe Francais De Pneumo-Cancerologie. 2006.
BibTeX
@misc{anon2006AMulti,
title = {A Multicenter Randomized Phase II Trial in NSCLC Stage IV and IIIB (T4 With Pleural Effusion) in Elderly Independent Patients the Schedule Docetaxel / Gemcitabine First Line Following by Erlotinib When Progression Versus Erlotinib First Line Following by/ Gemcitabine When Progression.},
author = {Anonymous},
journal = {Groupe Francais De Pneumo-Cancerologie},
year = {2006},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Groupe Francais De Pneumo-Cancerologie 2006
Open access · US-GOV
A Multicenter Randomized Phase II Trial in NSCLC Stage IV et IIIB in Elderly Dependent Patients With Evaluation of the Sequence Gemcitabine First Line Followed by Erlotinib When Progression Versus Erlotinib First Line Followed by Gemcitabine When Progression.
Hellenic Oncology Research Group 2006
Open access · US-GOV
A Multicenter Randomized Phase III Study of the Docetaxel and Gemcitabine Combination Versus Monotherapy With Gemcitabine as First-line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)
National Cancer Institute, Naples 2000
Open access · US-GOV
Evaluation of Activity and Toxicity of Polychemotherapy With 2-drug Combinations Containing Gemcitabine as First Line Treatment of Elderly Patients With Small Cell Lung Cancer
Genzyme, a Sanofi Company 2008
Open access · US-GOV
Phase II, Randomised, Double-blind, Two-arm, Parallel Study of Vandetanib (ZACTIMA™ , ZD6474) Plus Gemcitabine (Gemzar® ) or Gemcitabine Plus Placebo as First Line Treatment of Advanced (Stage IIIB or IV) Non Small Cell Lung Cancer (NSCLC) Elderly Patients.
Hellenic Oncology Research Group 2003
Open access · US-GOV
A Multicenter Randomized Phase II Study of Docetaxel Versus Vinorelbine as First-Line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)
Accelerated Community Oncology Research Network 2007
Open access · US-GOV